chronic hepatitis C
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. All study participants must meet the following criteria: (1) Age >=18 years, regardless of gender; (2) Positive for HCV antibodies, and the disease course has lasted at least 6 months; (3) Detectable serum HCV RNA; (4) HCV genotype 1. 2. Prospective study section: must meet the following criteria: (1) Intending to receive standard antiviral treatment with sofosbuvir/velpatasvir, sofosbuvir/velpatasvir/voxilaprevir, or glecaprevir/pibrentasvir. (2) Able to understand and willing to comply with the clinical trial protocol requirements, and voluntarily sign written informed consent. 3. Retrospective study section: must meet the following criteria: (1) Have complete medical records, with baseline, end-of-treatment, and 12-week post-treatment records available. (2) Have relatively complete information on direct medical costs incurred during treatment.
Exclusion criteria
Exclusion criteria: 1. Lack of basic demographic and clinical characteristics; 2. Non-genotype 1 individuals; 3. Participation in other drug clinical trials for HCV treatment within three months; 4. Missing data and not meeting basic statistical analysis requirements; 5. Previously received direct antiviral treatment; 6. Participants deemed unsuitable by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| High-precision HCV RNA;direct economic cost; | — |
Secondary
| Measure | Time frame |
|---|---|
| adverse reactions;Combination therapy; | — |
Countries
China
Contacts
West China Hospital of Sichuan University